Hologic Inc
NASDAQ:HOLX

Watchlist Manager
Hologic Inc Logo
Hologic Inc
NASDAQ:HOLX
Watchlist
Price: 74.89 USD 0.05% Market Closed
Market Cap: 16.7B USD

Hologic Inc
Investor Relations

Hologic Inc., headquartered in Marlborough, Massachusetts, crafts a narrative deeply intertwined with the vital mission of women's health. Established in 1985, the company has grown into a prominent player in the medical device and diagnostics realm. Hologic’s success is anchored in its core business sectors: Breast & Skeletal Health, Diagnostic Solutions, GYN Surgical, and Medical Aesthetics. The cornerstone of this expansive operation is innovation, driving the development of advanced technologies like 3D mammography systems that revolutionize breast cancer detection. This strategic focus on high-value diagnostics and medical equipment allows Hologic to capture significant market share, ensuring a steady revenue stream from both capital equipment sales and ongoing service and maintenance contracts.

Beyond its robust presence in imaging and diagnostics, Hologic amplifies its influence through a comprehensive array of solutions for early stage disease detection and treatment. Their Diagnostic Solutions arm, particularly strengthened by molecular diagnostic tests, is a response to the increasing global demand for rapid and accurate testing solutions—a need only intensified by recent global health challenges. These products not only provide critical tools for healthcare professionals but also secure recurring income for Hologic through the sale of consumables and tests. By embedding itself in the cycles of medical advancements and enhancing the standard of care, Hologic generates sustainable growth and remains a crucial ally in both public and specialized health sectors. The company’s blend of technology-driven products and strategic agility enables it to navigate dynamic markets while maintaining a resolute focus on improving health outcomes around the world.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Jul 30, 2025
AI Summary
Q3 2025

Revenue Beat: Hologic reported Q3 revenue of $1.024 billion, exceeding the high end of guidance by $14 million.

EPS Beat: Non-GAAP EPS was $1.08, up 1.9% year-over-year and $0.01 above the high end of guidance.

Margins: Operating margin stayed strong at just above 30%, while gross margin declined year-over-year due to product mix and a reserve related to discontinued products.

Breast Health Progress: The Breast Health segment improved sequentially, with 3D gantry shipments rising and interventional sales up 6% organically.

Endomag Acquisition: Endomag contributed nearly $20 million in Q3 and is running ahead of plan, helping drive growth.

Guidance Raised: Full-year revenue and EPS guidance midpoints were raised, with Q4 expected to show mid-single-digit revenue and high single-digit EPS growth.

Tariff Mitigation: Tariff headwinds have been reduced by half through supply chain changes, with expected impact of $10–12 million per quarter going forward.

Diagnostics and International: Diagnostics growth remains solid despite China and Africa headwinds; international markets remain a long-term growth driver.

Key Financials
Revenue
$1.024B
EPS
$1.08
Gross Margin
60.3%
Operating Margin
30.1%
Operating Cash Flow
$343M
Cash and Short-Term Investments
$1.88B
Net Leverage Ratio
0.6x
Diagnostics Revenue
$448.9M
Breast Health Revenue
$365.2M
Surgical Revenue
$178.4M
Skeletal Revenue
$31.3M
Interventional Sales (Breast Health)
$100M
Endomag Revenue Contribution
$20M
Q4 Tariff Expense
$8M
Tax Rate
19.25%
Net Margin
23.8%
Earnings Call Recording
Other Earnings Calls

Management

Mr. Stephen P. MacMillan
Chairman, CEO & President
No Bio Available
Ms. Karleen M. Oberton CPA
Chief Financial Officer
No Bio Available
Mr. Essex D. Mitchell
Chief Operating Officer
No Bio Available
Mr. John M. Griffin J.D.
General Counsel
No Bio Available
Mr. Jan Verstreken
Group President of International
No Bio Available
Mr. Paul Malenchini
Chief Information Officer
No Bio Available
Mr. Ryan M. Simon
Vice President of Investor Relations
No Bio Available
Ms. Diana De Walt SPHR
Senior Vice President of Global Human Resources
No Bio Available
Ms. Monica Aguirre Berthelot
VP & Chief of Staff
No Bio Available
Mr. Erik S. Anderson
Division President of Breast & Skeletal Health Solutions
No Bio Available

Contacts

Address
MASSACHUSETTS
Marlborough
250 Campus Dr
Contacts
+15082632900.0
www.hologic.com